CervoMed(CRVO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRVO CervoMed

Pre-Mkt 08-19 08:00:05 EDT

2.61

+0.00

0.00%

盘前2.60

-0.01-0.38%

07:53 EDT

High2.65	Low2.55	Vol318.96K
Open2.59	D1 Closing2.61	Amplitude3.83%
Mkt Cap39.46M	Tradable Cap29.22M	Total Shares15.12M
T/O828.84K	T/O Rate2.85%	Tradable Shares11.20M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRVO","market":"US","secType":"STK","nameCN":"CervoMed","latestPrice":2.61,"timestamp":1787083200000,"preClose":2.61,"halted":0,"volume":318961,"hourTrading":{"tag":"盘前","latestPrice":2.6,"preClose":2.61,"latestTime":"07:53 EDT","volume":1980,"amount":5204.03004,"timestamp":1787140424040,"change":-0.01,"changeRate":-0.003831,"amplitude":0.061303},"delay":0,"changeRate":0,"floatShares":11197200,"shares":15119100,"eps":-3.195903,"marketStatus":"Pre-Mkt","change":0,"latestTime":"08-19 08:00:05 EDT","open":2.59,"high":2.65,"low":2.55,"amount":828840.7633806,"amplitude":0.038314,"askPrice":2.61,"askSize":20,"bidPrice":2.55,"bidSize":15,"shortable":3,"etf":0,"ttmEps":-3.195903,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787146200000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":2.61,"preHourTrading":{"tag":"盘前","latestPrice":2.6,"preClose":2.61,"latestTime":"07:53 EDT","volume":1980,"amount":5204.03004,"timestamp":1787140424040,"change":-0.01,"changeRate":-0.003831,"amplitude":0.061303},"postHourTrading":{"tag":"盘后","latestPrice":2.67,"preClose":2.61,"latestTime":"19:48 EDT","volume":4216,"amount":10997.2258,"timestamp":1787096905201,"change":0.06,"changeRate":0.022989,"amplitude":0.034483},"volumeRatio":0.6722721485656801},"requestUrl":"/m/hq/s/CRVO/tweets","defaultTab":"tweets","newsList":[{"id":"2658974921","title":"CervoMed Price Target Maintained with a $25.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2658974921","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658974921?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:35","pubTimestamp":1786534500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658197967","title":"CervoMed: Buy Rating Reiterated as Dementia Pipeline Advances; $25 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2658197967","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658197967?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:36","pubTimestamp":1786530976,"startTime":"0","endTime":"0","summary":"Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on CervoMed and keeping the price target at $25.00. Ram Selvaraju has given his ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cervomed-buy-rating-reiterated-as-dementia-pipeline-advances-25-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cervomed-buy-rating-reiterated-as-dementia-pipeline-advances-25-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658936286","title":"CervoMed is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2658936286","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658936286?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:23","pubTimestamp":1786364580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658443933","title":"CervoMed Q2 Net Loss Lower than Estimates as Costs Drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2658443933","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658443933?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:38","pubTimestamp":1786361915,"startTime":"0","endTime":"0","summary":"CervoMed Q2 net loss lower than estimates as costs dropOverviewUS biotech developer's Q2 net loss was lower than analyst expectationsCompany completed $20.5 mln equity financings, extending cash runwa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470AO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXSM","BK4505","LU2324357040.USD","BK4585","PTH","BK4007","BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658933970","title":"CervoMed Q2 EPS $(0.64) Misses $(0.60) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658933970","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658933970?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:33","pubTimestamp":1786361613,"startTime":"0","endTime":"0","summary":"CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.60) by 6.67 percent. This is a 8.57 percent increase over losses of $(0.70) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61070579/cervomed-q2-eps-0-64-misses-0-60-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658933484","title":"Press Release: CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658933484","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658933484?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:30","pubTimestamp":1786361400,"startTime":"0","endTime":"0","summary":"partnership to advance its neflamapimod program into a Phase 3 clinical. -- CervoMed received a notice of allowance from the U.S. Patent and. Trademark Office in June 2026 for a new patent covering the use of","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","BK4110","LU0205194284.USD","BK4139","DLB","LU0240878834.USD","LU0240877869.USD","LU0348723411.USD","BK4132","AAIC","LU0345774391.USD","CRVO","LU0205193047.USD","LU0345774631.USD","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657621505","title":"CervoMed Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657621505","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657621505?lang=en_us&edition=fundamental","pubTime":"2026-08-08 06:01","pubTimestamp":1786140102,"startTime":"0","endTime":"0","summary":"CervoMed Inc reports results for the quarter ended June 30 - Earnings SummaryCervoMed IncCRVO.OQreported a quarterly adjusted loss of 64 cents per share for the quarter ended June 30, higher than the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4442MK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657626905","title":"Cervomed Q2 FY26 Net Loss Widens 5% to $6.57 Million; Revenue Turns to None","url":"https://stock-news.laohu8.com/highlight/detail?id=2657626905","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657626905?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:28","pubTimestamp":1786134486,"startTime":"0","endTime":"0","summary":"Cervomed Q2 FY26 net loss widens 5% to $6.57 million; revenue turns to noneCervomed posted a net loss of $6.57 million in Q2, widening 5% from the prior-year quarter.Operating loss was $6.68 million, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL1JMhz3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657542295","title":"CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2657542295","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657542295?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:30","pubTimestamp":1785929400,"startTime":"0","endTime":"0","summary":"BOSTON, Aug.  05, 2026  (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/05/3339214/0/en/CervoMed-to-Participate-in-Fireside-Chat-to-Highlight-Recent-Progress-in-the-Neflamapimod-Clinical-Development-Program-at-the-Canaccord-Genuity-46th-Annual-Growth-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRGS","BK4097","BK4139","LU2065732104.USD","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656551361","title":"CervoMed Inc Expected to Post a Loss of 87 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2656551361","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656551361?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:23","pubTimestamp":1785849786,"startTime":"0","endTime":"0","summary":"CervoMed Inc <CRVO.OQ> expected to post a loss of87cents a share - Earnings PreviewCervoMed IncCRVO.OQCRVO.Ois expected to  show a fall in quarterly revenue when it reports  results on August 6 (estim","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL8N4411P7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656555079","title":"CervoMed’s neflamapimod gains UK Innovation Passport","url":"https://stock-news.laohu8.com/highlight/detail?id=2656555079","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656555079?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:19","pubTimestamp":1785845960,"startTime":"0","endTime":"0","summary":"CervoMed ( ($CRVO) ) has provided an announcement. On August 4, 2026, CervoMed announced that neflamapimod, its oral small-molecule drug targeting ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cervomeds-neflamapimod-gains-uk-innovation-passport?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cervomeds-neflamapimod-gains-uk-innovation-passport?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656553429","title":"CervoMed Says UK Grants ILAP Innovation Passport for Neflamapimod in Lewy Body Dementia","url":"https://stock-news.laohu8.com/highlight/detail?id=2656553429","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656553429?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:52","pubTimestamp":1785844374,"startTime":"0","endTime":"0","summary":"CervoMed says UK grants ILAP Innovation Passport for neflamapimod in Lewy body dementiaCervoMed’s neflamapimod received an Innovation Passport under the UK Innovative Licensing and Access Pathway for ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDLWFK2r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656115539","title":"CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (Ilap) for Treatment of Dementia with Lewy Bodies (Dlb)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656115539","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656115539?lang=en_us&edition=fundamental","pubTime":"2026-08-04 17:15","pubTimestamp":1785834900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nTUA7XJGMY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651118452","title":"Cervomed Price Target Maintained with a $25.00/share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2651118452","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651118452?lang=en_us&edition=fundamental","pubTime":"2026-07-15 18:50","pubTimestamp":1784112600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings(END) Dow Jones NewswiresJuly 15, 2026 06:50 ET","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651582584","title":"CervoMed advances neflamapimod strategy with new DLB data","url":"https://stock-news.laohu8.com/highlight/detail?id=2651582584","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651582584?lang=en_us&edition=fundamental","pubTime":"2026-07-15 15:44","pubTimestamp":1784101487,"startTime":"0","endTime":"0","summary":"CervoMed ( ($CRVO) ) has issued an update. On July 14, 2026, CervoMed reported new clinical, plasma biomarker and imaging data for neflamapimod in ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cervomed-advances-neflamapimod-strategy-with-new-dlb-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cervomed-advances-neflamapimod-strategy-with-new-dlb-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0348723411.USD","LU0345774631.USD","LU0240878834.USD","BK4097","LU0205194284.USD","BK4139","LU0205193047.USD","CRVO","LU0240877869.USD","LU0345774391.USD","DLB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651108822","title":"Cervomed Reports New Phase 2b Data Supporting Neflamapimod 50 Mg TID Dose for Planned DLB Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2651108822","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651108822?lang=en_us&edition=fundamental","pubTime":"2026-07-14 19:35","pubTimestamp":1784028920,"startTime":"0","endTime":"0","summary":"CervoMed reports new Phase 2b data supporting neflamapimod 50 mg TID dose for planned DLB Phase 3 trialCervoMed presented new AAIC 2026 analyses supporting 50 mg three-times-daily neflamapimod as the ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nNDL9cVVpd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651170037","title":"Cervomed Announces New Clinical, Plasma Biomarker and Imaging Data at Aaic 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (dlb)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651170037","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651170037?lang=en_us&edition=fundamental","pubTime":"2026-07-14 19:30","pubTimestamp":1784028601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nTUA3WFHYW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651136371","title":"Cervomed Price Target Maintained with a $25.00/share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2651136371","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651136371?lang=en_us&edition=fundamental","pubTime":"2026-07-13 18:25","pubTimestamp":1783938300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings(END) Dow Jones NewswiresJuly 13, 2026 06:25 ET","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650929730","title":"Cervomed Price Target Maintained with a $25.00/share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2650929730","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650929730?lang=en_us&edition=fundamental","pubTime":"2026-07-09 19:59","pubTimestamp":1783598340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings(END) Dow Jones NewswiresJuly 09, 2026 07:59 ET","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650929961","title":"CervoMed completes enrollment in neflamapimod study","url":"https://stock-news.laohu8.com/highlight/detail?id=2650929961","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650929961?lang=en_us&edition=fundamental","pubTime":"2026-07-09 19:40","pubTimestamp":1783597246,"startTime":"0","endTime":"0","summary":"CervoMed (CRVO) announced that it has completed enrollment in the Phase 2a study of neflamapimod for the treatment of nfvPPA, a type of FTD. Interi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomed-completes-enrollment-in-neflamapimod-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomed-completes-enrollment-in-neflamapimod-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cervomed.com","stockEarnings":[{"period":"1week","weight":-0.1553},{"period":"1month","weight":-0.1526},{"period":"3month","weight":-0.1944},{"period":"6month","weight":-0.501},{"period":"1year","weight":-0.7345},{"period":"ytd","weight":-0.6696}],"compareEarnings":[{"period":"1week","weight":-0.004},{"period":"1month","weight":0.0325},{"period":"3month","weight":0.0353},{"period":"6month","weight":0.1212},{"period":"1year","weight":0.193},{"period":"ytd","weight":0.1254}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.023389},{"month":2,"riseRate":0.5,"avgChangeRate":0.085839},{"month":3,"riseRate":0.5,"avgChangeRate":0.326048},{"month":4,"riseRate":0.3,"avgChangeRate":-0.063988},{"month":5,"riseRate":0.4,"avgChangeRate":0.116259},{"month":6,"riseRate":0.1,"avgChangeRate":-0.109707},{"month":7,"riseRate":0.2,"avgChangeRate":-0.086929},{"month":8,"riseRate":0.7,"avgChangeRate":0.06984},{"month":9,"riseRate":0.111111,"avgChangeRate":-0.117703},{"month":10,"riseRate":0.111111,"avgChangeRate":-0.039339},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.045938},{"month":12,"riseRate":0.3,"avgChangeRate":-0.206034}],"exchange":"NASDAQ","name":"CervoMed","nameEN":"CervoMed"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CervoMed(CRVO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CervoMed(CRVO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CervoMed,CRVO,CervoMed股票,CervoMed股票老虎,CervoMed股票老虎国际,CervoMed行情,CervoMed股票行情,CervoMed股价,CervoMed股市,CervoMed股票价格,CervoMed股票交易,CervoMed股票购买,CervoMed股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CervoMed(CRVO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CervoMed(CRVO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}